- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05038254
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
There Is No Place Like Home- A Pragmatic Effectiveness Trial of Technology-Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
Study Overview
Status
Conditions
- Metastatic Pancreatic Carcinoma
- Stage IV Pancreatic Cancer AJCC v8
- Clinical Stage IV Gastric Cancer AJCC v8
- Stage IV Colon Cancer AJCC v8
- Stage IV Rectal Cancer AJCC v8
- Stage IVA Colon Cancer AJCC v8
- Stage IVA Rectal Cancer AJCC v8
- Stage IVB Colon Cancer AJCC v8
- Stage IVB Rectal Cancer AJCC v8
- Stage IVC Colon Cancer AJCC v8
- Stage IVC Rectal Cancer AJCC v8
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
- Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Clinical Stage IVA Gastric Cancer AJCC v8
- Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
- Clinical Stage IVB Gastric Cancer AJCC v8
- Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
- Pathologic Stage IV Gastric Cancer AJCC v8
- Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
- Metastatic Esophageal Carcinoma
- Metastatic Gastric Carcinoma
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8
- Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
- Metastatic Colon Carcinoma
- Metastatic Malignant Digestive System Neoplasm
- Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
- Metastatic Rectal Carcinoma
- Metastatic Liver Carcinoma
- Metastatic Malignant Thoracic Neoplasm
- Metastatic Malignant Small Intestinal Neoplasm
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. Determine the efficacy of remote patient monitoring (RPM) on improving clinical outcomes.
SECONDARY OBJECTIVE:
I. Evaluate the following patient-centered outcomes: treatment delays, health-related quality-of-life (HRQOL), patient activation, and family caregiver-experience.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive standard of care consisting of oncology care provided via telemedicine.
ARM II: Patients receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ryan W Huey, MD
- Phone Number: 713-792-2828
- Email: remotemonitoringprogram@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Principal Investigator:
- Ryan W Huey
-
Contact:
- Ryan W Huey
- Phone Number: 713-792-2828
- Email: remotemonitoringprogram@mdanderson.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults (≥ 18 years)
- English- and Spanish-fluent participants with thoracic and/or gastrointestinal cancers who are scheduled to initiate or continue outpatient chemotherapy at either MDACC (Texas Medical Center campus and any Houston-area location) or MDACC oncology clinic at Lyndon B Johnson (LBJ) hospital
- Their adult (≥18 years) patient-identified or self-identified primary caregivers (MDACC only)
- Participants on combination chemotherapy and immunotherapy or combination chemotherapy and biologic will also be eligible for inclusion.
- Participants may participate if they do not have a caregiver, or if their caregiver declines participation; however, caregivers of MDACC participants may participate only if the participant consents.
Exclusion Criteria:
- Participants who are receiving investigational new drug treatments or concurrently enrolled in a phase 1 clinical trial will be excluded due to the associated structured reporting and regulatory requirements.
- Participants with a requirement for inpatient infusion (i.e. CAR-T cell therapy), living in institutional settings (i.e. prison, nursing homes), with a history of dementia, physical disability or neurological deficits that prohibit ability to report symptom burden will also be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I (standard of care)
Patients receive standard of care consisting of oncology care provided via telemedicine.
|
Ancillary studies
Receive standard of care telemedicine
Other Names:
|
Experimental: Arm II (standard of care, remote monitoring)
Patients receive standard of care consisting of oncology care provided via telemedicine.
Patients also undergo remote monitoring.
|
Ancillary studies
Receive standard of care telemedicine
Other Names:
Undergo remote monitoring
Other Names:
|
Experimental: Arm III (standard of care, remote monitoring, biometrics)
Patient receive standard of care consisting of oncology care provided via telemedicine.
Patients also undergo remote monitoring and biometric monitoring.
|
Ancillary studies
Receive standard of care telemedicine
Other Names:
Undergo remote monitoring
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of acute care visits
Time Frame: Up to 3 months
|
Defined as the proportion of unique oncology patients with emergency room visits or hospital admission over a 3-month period.
|
Up to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in health-related quality of life (HRQOL)
Time Frame: Baseline to 6 months
|
HRQOL will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) Profile-29 version 2.1.
|
Baseline to 6 months
|
Change in patient engagement
Time Frame: Baseline to 6 months
|
Patient engagement will be evaluated with the 13-item Patient Activation Measure (PAM), which assesses knowledge, skill, and self-efficacy for self-management of health
|
Baseline to 6 months
|
Change in symptom management
Time Frame: Baseline to 6 months
|
Daily symptoms will be measured using the Common Terminology Criteria for Adverse Events version 5.
|
Baseline to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ryan W Huey, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Endocrine Gland Neoplasms
- Liver Diseases
- Head and Neck Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Liver Neoplasms
- Rectal Diseases
- Esophageal Diseases
- Colorectal Neoplasms
- Pancreatic Diseases
- Neoplasms, Connective Tissue
- Neoplasms, Squamous Cell
- Neoplasms
- Stomach Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Adenocarcinoma
- Rectal Neoplasms
- Pancreatic Neoplasms
- Gastrointestinal Stromal Tumors
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Colonic Neoplasms
- Esophageal Squamous Cell Carcinoma
- Intestinal Neoplasms
- Thoracic Neoplasms
Other Study ID Numbers
- 2020-0702 (Other Identifier: M D Anderson Cancer Center)
- NCI-2021-07464 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Pancreatic Carcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal AdenocarcinomaUnited States
-
General Oncology, Inc.Myriad Genetics, Inc.RecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation | Pancreatic Acinar Cell Carcinoma | Metastatic Pancreatic Cancer | Breast Cancer Metastatic | HER2-negative Breast Cancer | Metastatic Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
SanofiActive, not recruitingBreast Cancer Metastatic | Pancreatic Carcinoma MetastaticSpain, Korea, Republic of, Turkey, Chile, Netherlands, Russian Federation, Taiwan, United States, Argentina, Hungary
-
Roswell Park Cancer InstituteIpsenActive, not recruitingUnresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditionsUnited States
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...CompletedMetastatic Pancreatic CarcinomaUnited States
-
Maria LiljeforsKarolinska University Hospital; Karolinska Institutet; CelgeneCompletedPancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma MetastaticSweden
-
H. Lee Moffitt Cancer Center and Research InstituteGenentech, Inc.CompletedMetastatic Pancreatic CarcinomaUnited States
-
IRCCS San RaffaeleRecruitingHepatocellular Carcinoma | Metastatic Cancer | Primary Liver Cancer | Cholangiocarcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer | Metastatic Colon CancerItaly
-
Georgetown UniversityNational Cancer Institute (NCI); Mayo Clinic; Emory University; Indiana University and other collaboratorsTerminatedMetastatic Colorectal Cancer | Pancreatic Adenocarcinoma | Colorectal Adenocarcinoma | Metastatic Pancreatic CancerUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation